Zevra Therapeutics (ZVRA) Other Accumulated Expenses (2015 - 2026)

Zevra Therapeutics' Other Accumulated Expenses history runs 12 years deep, the most recent figure standing at $1.4 million for Q1 2026.

• Quarterly Other Accumulated Expenses fell 58.6% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (down 58.6% YoY) and the FY2025 annual result came in at $1.4 million, down 39.73% from the prior year.
• Other Accumulated Expenses was $1.4 million for Q1 2026 at Zevra Therapeutics, up from $1.4 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $9.0 million in Q3 2025 and bottomed at $7000.0 in Q1 2022.
• A 5-year average of $2.3 million and a median of $1.4 million in 2026 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses tumbled 98.18% — and 2023, when it surged 4214.29%.
• Zevra Therapeutics' Other Accumulated Expenses stood at $629000.0 in 2022, then jumped by 301.27% to $2.5 million in 2023, then declined by 10.46% to $2.3 million in 2024, then tumbled by 39.73% to $1.4 million in 2025, then rose by 3.38% to $1.4 million in 2026.
• Business Quant data shows ZVRA's Other Accumulated Expenses at $1.4 million in Q1 2026, $1.4 million in Q4 2025, and $9.0 million in Q3 2025.